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Abstract
Background: IQGAP1 and IQGAP2 are homologous members of the IQGAP family of scaffold proteins.
Accumulating evidence implicates IQGAPs in tumorigenesis. We recently reported that IQGAP2 deficiency leads to
the development of hepatocellular carcinoma (HCC) in mice. In the current study we extend these findings, and
investigate IQGAP1 and IQGAP2 expression in human HCC.
Methods: IQGAP1 and IQGAP2 protein expression was assessed by Western blotting and immunohistochemistry.
IQGAP mRNA was measured by quantitative RT-PCR. The methylation status of the Iqgap2 promoter was
determined by pyrosequencing of bisulfite-treated genomic DNA.
Results: IQGAP1 and IQGAP2 expression was reciprocally altered in 6/6 liver cancer cell lines. Similarly,
immunohistochemical staining of 82 HCC samples showed that IQGAP2 protein expression was reduced in 64/82
(78.0%), while IQGAP1 was present in 69/82 (84.1%). No IQGAP1 staining was detected in 23/28 (82.1%) normal
livers, 4/4 (100.0%) hepatic adenomas and 23/23 (100.0%) cirrhosis cases, while IQGAP2 was increased in 22/28
(78.6%), 4/4 (100.0%) and 23/23 (100.0%), respectively. Although the Iqgap2 promoter was not hypermethylated in
HCC at any of the 25 CpG sites studied (N = 17), IQGAP2 mRNA levels were significantly lower in HCC specimens
(N = 23) than normal livers (N = 6).
Conclusions: We conclude that increased IQGAP1 and/or decreased IQGAP2 contribute to the pathogenesis of
human HCC. Furthermore, downregulation of IQGAP2 in HCC occurs independently of hypermethylation of the
Iqgap2 promoter. Immunostaining of IQGAP1 and IQGAP2 may aid in the diagnosis of HCC, and their
pharmacologic modulation may represent a novel therapeutic strategy for the treatment of liver cancer.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most common cause of
cancer-related death in the world [1]. It accounts for
over 80% of all human liver cancer, and is responsible
for between 500,000 and 1 million worldwide deaths
annually [2]. Predisposing factors for HCC include
chronic hepatitis B and C virus infections (HBV and
H C V ,r e s p e c t i v e l y ) ,e x p o s u r et oa f l a t o x i nB 1 ,c h r o n i c
alcohol consumption, or any hepatic disease associated
with cirrhosis. Nevertheless, the molecular pathogenesis
of HCC remains largely unknown. Recognized abnorm-
alities in HCC include aberrant signaling through the
mitogen-activated protein kinase, PI3K/Akt and mTOR
pathways, and overactivation of several growth factor
receptors (although research has focused mainly on the
epidermal growth factor receptor) [3]. Recurrent allelic
losses or gains have also been detected on 14 chromo-
some arms in more than 30% of all HCCs analyzed [4].
D e s p i t et h el a r g en u m b e ro fs c i e n t i f i ca n dc l i n i c a ls t u -
dies performed to date, overall survival of patients with
HCC has not improved in the last two decades.
There are three IQGAP proteins in humans, termed
IQGAP1, IQGAP2 and IQGAP3 [5]. IQGAP1 is the best-
characterized member of the IQGAP family. Unlike
IQGAP2, which is expressed primarily in the liver and pla-
telets [6,7], and IQGAP3, where expression is limited to
the brain [8], IQGAP1 is expressed ubiquitously [5].
IQGAP1 binds F-actin through calponin homology
domains [9], interacts with multiple calmodulin molecules
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2+-regulated fashion) through repetitive IQ motifs
(IQxxxRGxxR), and binds the Rho GTPases Cdc42 and
Rac1 by means of a C-terminal RasGAP-related domain
[5]. In addition to the established binding partners listed
above, IQGAP1 associates with the ERK and MEK kinases
[10,11], b-catenin [12,13], E-cadherin [14,15], adenoma-
tous polyposis coli (APC) [16], mTOR [17], and Sec 3 and
8 (which are involved in exocytosis and invasion) [18].
IQGAP1 has been shown to regulate cell proliferation and
migration in vitro [19-21], and is overexpressed in aggres-
sive cancers [22]. In order to elucidate the physiological
functions of IQGAP2 (one of the less well studied
IQGAP1 homologs), a conventional Iqgap2 knockout
mouse was generated in our laboratory [6]. We showed
that IQGAP2 deficiency results in an 86% incidence of
HCC. Of equal importance, mice deficient in both Iqgap1
and Iqgap2 (Iqgap1
-/-/Iqgap2
-/-) display relative protection
against HCC, and have improved long-term survival.
These data suggest that, at least in mice, changes in
IQGAP expression contribute to the pathogenesis of HCC.
In humans, Iqgap2 silencing, by hypermethylation,
contributes to the pathogenesis of certain forms of gas-
trointestinal cancer [23]. For example, Iqgap2 methyla-
tion was detected in 47% of gastrointestinal tumors, but
not in normal mucosa. Additionally, IQGAP2 protein
was absent from all samples in which the Iqgap2 promo-
ter was hypermethylated, and a significant correlation
was noted between Iqgap2 methylation and cancer
aggressiveness. These data, viewed in conjunction with
the data from our mouse model, prompted us to
hypothesize that decreased IQGAP2 expression, as a
result of hypermethylation of the Iqgap2 promoter, may
contribute to the pathogenesis of human HCC. In the
present study, our aim was to examine IQGAP1 and
IQGAP2 expression in human HCC, their sensitivity
and specificity as biomarkers of this type of tumor, and
the methylation profile of the Iqgap2 promoter.
Methods
Cell Culture and Western Blotting
All cells were maintained in Dulbecco’s Modified Eagles
Medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum and 1% (v/v) penicillin/streptomycin. For
IQGAP1 and IQGAP2 expression analyses, cell mono-
layers were placed on ice, washed twice with ice-cold
phosphate-buffered saline (PBS), and lysed in lysis buffer
(50 mM Tris (pH 8.0), 100 mM NaF, 30 mM Na4P2O7,
2m MN a 2MoO4, 5 mM EDTA, 2 mM Na3VO4) supple-
mented with 10 μg/ml aprotinin, 10 μg/ml leupeptin
and 1 mM phenylmethylsulfonyl fluoride. Clarified cell
lysates were equalized for protein concentration using
t h em o d i f i e dB r a d f o r dA s s a y( B i o - R a dL a b o r a t o r i e s ,
Hercules, CA), resolved by SDS-PAGE, and processed
by Western blotting. IQGAP1 and IQGAP2 expression
was measured by Western blotting cell lysates with rab-
bit polyclonal anti-IQGAP1 (generated and character-
ized previously in our laboratory [24]; dilution 1:1,000)
or mouse monoclonal anti-IQGAP2 (Upstate Biotech-
nology, Lake Placid, NY; clone BB9; dilution 1:1,000)
antibodies, respectively. All blots were also probed with
mouse monoclonal anti-b-Tubulin (Cell Signaling Tech-
nology, Danvers, MA; dilution 1:2,000) antibody to ver-
ify protein loading.
Study Groups
A total of 66 biopsy (N = 26) and surgical resection
(N = 40) routinely processed formalin-fixed paraffin-
embedded (FFPE) specimens, from 66 patients (M/F
ratio; 46/20, median age; 60.5 years), were randomly
selected from the tissue archives of the Department of
Pathology, Brigham and Women’s Hospital, between the
years 2005 and 2009. These included 30 HCC speci-
mens, 4 hepatic adenomas, 23 cases of cirrhosis and 9
normal livers. In addition, a tissue microarray (TMA)
(US Biomax, Rockville, MD) containing 52 HCC speci-
mens and 19 normal livers (M/F ratio; 62/9, median
age; 51 years) was also included in the study (Table 1).
Hematoxylin and eosin stained sections were reviewed
independently by two pathologists for confirmation of
the diagnoses and grading of the tumors (according to
International Union against Cancer (UICC) guidelines).
Table 1 Patient demographics and pathologic
information
Feature BWH (%) TMA (%) Total (%)
Sex
Male 46/66
(69.7)
62/71
(87.3)
108/137
(78.9)
Female 20/66
(30.3)
9/71 (12.7) 29/137 (21.1)
Median Age (range) 60.5 (30-
86)
51 (19-78) 56 (19-86)
Histopathological Diagnosis
Normal 9/66 (13.6) 19/71
(26.8)
28/137 (20.4)
Adenoma 4/66 (6.1) 0/71 (0.0) 4/137 (2.9)
Cirrhosis 23/66
(34.8)
0/71 (0.0) 23/137 (16.8)
Carcinoma 30/66
(45.5)
52/71
(73.2)
82/137 (59.9)
Hepatocellular Carcinoma
Grade
Well Differentiated 8/30 (26.7) 11/52
(21.1)
19/82 (23.2)
Moderately Differentiated 13/30
(43.3)
25/52
(48.1)
38/82 (46.3)
Poorly Differentiated 9/30 (30.0) 16/52
(30.8)
25/82 (30.5)
BWH, Brigham and Women’s Hospital; TMA, tissue microarray.
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Immunohistochemistry
FFPE blocks from Brigham and Women’s Hospital were
cut into 5 μm thick tissue sections and slides prepared
using standard techniques. Mounted tissue sections were
baked at 60°C for 20 min, deparaffinized in xylene and
rehydrated through graded alcohols. Antigens were
retrieved by heating in 1 μMs o d i u mc i t r a t e( p H6 . 0 )i na
pressure cooker at 125°C for 30 s. Non-specific staining
was blocked using Dako Protein Block (Dako, Carpin-
teria, CA) according to the manufacturer’si n s t r u c t i o n s .
Anti-IQGAP1 (dilution 1:2,000) and anti-IQGAP2 (dilu-
tion 1:100) primary antibodies were diluted in Dako
Antibody Diluent and incubated with the tissue sections
for 1 h at room temperature. Staining was visualized
using Dako Envision and developed with a DAB Chro-
mogen substrate. Immediately after visualization, sections
were dipped in DAB Enhancer, counterstained with
hematoxylin, dehydrated through graded alcohols and
xylene, and mounted. Appropriate positive and negative
controls were used throughout all staining and interpre-
tation. Antibody specificity for each IQGAP has pre-
viously been validated using protein from Iqgap1
-/- and
Iqgap2
-/- mice [6]. Nevertheless, we confirmed these
results using a panel of human HCC cell lines (Figure 1).
Those cells with higher levels of IQGAP1 had lower
levels of IQGAP2, and those with higher levels of
IQGAP2 had lower levels of IQGAP1 (Figure 1). These
data strongly suggest that each IQGAP antibody is highly
specific for its respective protein.
Immunostaining Interpretation
IQGAP1 and IQGAP2 immunostaining was blindly eval-
uated by two independent pathologists with a high
degree of interobserver agreement (>90%). Staining for
each antibody was considered positive if more than 10%
of cells stained strongly in the cytoplasm.
Quantitative real-time PCR
A commercial qRT-PCR TissueScan Array (OriGene,
Rockville, MD) containing 23 individual cDNAs from
patients with primary HCC of different stages, and 6
individual cDNAs from normal livers (M/F ratio; 19/10,
median age; 63 years), was used for quantification of
IQGAP1 and IQGAP2 mRNA transcripts. Each cDNA
was normalized by the manufacturer against b-actin by
RT-PCR. Oligonucleotide primer pairs were generated
using Primer3 software (http://www.genome.wi.mit.edu),
a n dd e s i g n e dt oa m p l i f y~ 2 0 0b pP C Rp r o d u c t sa ta n
annealing temperature of 71°C. Primer sequences were
as follows: IQGAP1, forward: 5’-TCCAATAAGAT
GTTTCTGGGAGAT-3’; reverse: 5’-GATGATTTCACC
AATGGAAATGTA-3’. IQGAP2, forward: 5’-GATGTA
GGCATTTTCGATGTAAGA-3’; reverse: 5’-ATTTCTG
TAGGCACTTCACTTTCC-3’. PCR reactions were
initiated at 95°C for 15 s and cycled 39 times at 94°C
for 30 s, 55°C for 30 s and 72°C for 30 s. mRNA was
quantified by monitoring real-time fluorimetric intensity
of SYBR green I at a reading temperature of 70°C using
a 7300 thermocycler (Applied Biosystems, Foster City,
CA). Relative mRNA abundance was determined using
the comparative threshold cycle number (Δ-Ct method)
[25], and normalized to the cDNA amount as previously
described [26].
Promoter Methylation Assay by Pyrosequencing
Genomic DNA isolation from FFPE liver samples
Tissue sections (3 per preparation) were deparaffinized
in xylene for 5 min, rehydrated through graded alcohols
and digested using 200 μg/ml proteinase K at 54°C over-
night. Formalin cross-linking was reversed by incubation
at 90°C for 1 h, and genomic DNA was isolated using
the QIAamp DNA FFPE Tissue kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions.
Bisulfite treatment of genomic DNA
Bisulfite conversion of unmethylated CpG islands was
completed using the EZ DNA Methylation Gold kit
(Zymo Research, Orange, CA) according to the manufac-
turer’s instructions. Bisulfite treatment converts all non-
methylated cytosines (C) into thymidines (T), whereas all
methylated Cs remain. Briefly, 1-2 μgo fg e n o m i cD N A
was treated with CT conversion reagent for 10 min at
98°C and 190 min at 64°C. After conversion, DNA was
loaded onto a Zymo Spin IC column, washed with
M-Wash buffer, and treated with M-Desulphonation
Figure 1 IQGAP1 and IQGAP2 are reciprocally altered in
human liver cancer cell lines. Equal amounts of cell lysate from
the cultured liver cancer cell lines indicated were resolved by SDS-
PAGE and processed by Western blotting. Immunoblots were
probed with anti-IQGAP1, anti-IQGAP2 and anti-b-Tubulin
antibodies. Representative data from four independent experiments
are shown.
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DNA was eluted from the column in 12 μl of M-Elution
buffer, and the resulting DNA yield was evaluated using a
2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA).
Assay design and PCR
The pyrosequencing technique allows quantitative deter-
mination of methylation at selected CpG sites in the
gene promoter region [27]. A genomic DNA sequence
corresponding to the human Iqgap2 promoter region
(Chromosome 5:75734588 - 75735487) was downloaded
from the UCSC Genome browser (http://genome.ucsc.
edu/), and a text editor used to model bisulfite conver-
sion of methylated CpG sites. The resulting modified
DNA sequence was imported into Assay Design soft-
ware (version 1.0.6) and used to generate primers for
pyrosequencing. In parallel, primers for PCR amplifica-
tion of the Iqgap2 promoter region were designed using
the internet-based BiSearch primer design algorithm for
bisulfite-converted DNA sequences (http://bisearch.
enzim.hu). This algorithm allows searching of the entire
bisulfite-converted human genome to identify primer
pairs that exclude non-specific amplification (which is
especially important for amplification of highly redun-
dant promoter sequences) [28]. Primer sequences are
listed in Additional File 1, and their location in the
Iqgap2 promoter is shown in Additional File 2. Since
the amount of DNA isolated from FFPE sections was
insufficient to obtain a good quality product in one PCR
reaction, two-round PCR amplification was used. For
the first round, F1 and R1 were used as forward and
reverse primers, respectively (Additional File 2). For the
second round, F1 and Bio-R2 were used as forward and
biotinylated-reverse primers, respectively (Additional
File 2). As the GC-content of bisulfite-treated DNA was
substantially altered, gradient PCR was used to optimize
the annealing temperature (T between 50-60°C).
An annealing temperature of 57°C resulted in the high-
est yield of PCR product, and no contaminating non-
specific products were detected. PCR amplification was
carried out according to the Qiagen protocol. Briefly,
10 μl of bisulfite-treated DNA was mixed with 10 μlo f
2 × HotStarTaq Plus Master Mix. Primers were added
at a final concentration of 0.5 μM in a reaction volume
of 21 μl. PCR reactions were initiated at 95°C for 5 min,
cycled 40 times at 94°C for 15 s, 57°C for 1 min and
65°C for 1 min, and completed with a final elongation
step of 65°C for 10 min. PCR products were examined
by electrophoresis on a 1.5% agarose gel in order to
confirm the specificity of amplification. For the second
round of PCR amplification, samples were diluted 100
times in TE Buffer (pH 7.5) and 2 μl was used per reac-
tion. Second round PCR amplification was carried out
as above.
Pyrosequencing
The 150 bp Iqgap2 promoter region was divided into
three separate areas and three different sequencing pri-
mers, S1, S2 and S3, were used to sequence them (Addi-
tional File 1 and Additional File 2). The reaction was
carried out in 96 well plates according to the manufac-
turer’s instructions. Briefly, a biotin-labeled PCR product
was captured on Streptavidin Sepharose High Perfor-
mance beads (Amersham Biosciences, Uppsala, Sweden)
in 80 μl of binding buffer. Beads containing the immobi-
l i z e dP C Rp r o d u c tw e r ew a s hed with 70% ethanol, and
the PCR product was denatured in 0.2 M NaOH. Pyro-
sequencing primer (0.3 μM) was annealed to the puri-
fied single-stranded PCR product at 80°C, and
pyrosequencing was performed using a PyroMark MD
pyrosequencer (Qiagen, Valencia, CA). The degree of
methylation for each CpG site was expressed as a per-
centage of methylated cytosines over the sum of total
cytosines. Non-CpG cytosine residues were used as
built-in controls to verify bisulfite conversion. Genomic
DNA from the Kato III human gastric cancer cell line
(ATCC, Rockville, MD), which is known to have a
hypermethylated Iqgap2 promoter [23], was used as a
positive control in each experiment. Each assay also
contained controls for self-annealing of sequencing pri-
mers and for self-annealing of a single-stranded PCR
product.
Statistical Analysis
The two-tailed Student’s t test was used to analyze data
from qRT-PCR experiments. For methylation studies,
statistical significance was determined by analysis of var-
iance (ANOVA), while correlation coefficients were
established using regression analysis. For all compari-
sons, a p value < 0.05 was used to establish statistical
significance. Box-and-whisker plots were used to display
5 descriptive statistics: the median, the lower and upper
quartiles, and the minimum and maximum data values.
The bottom and top of the box represent the 25
th and
the 75
th percentiles (the lower and upper quartiles,
respectively), and the band near the middle of the box
represents the median (the 50
th percentile). Whiskers
(error bars) below and above the box indicate the 10th
and 90th percentiles (shown only for plots with N = 9
or more). Symbols outside whiskers represent outliers.
Results
IQGAP1 and IQGAP2 are Reciprocally Altered in Human
Liver Cancer Cell Lines
We determined the relative amounts of IQGAP1 and
IQGAP2 in a panel of human liver cancer cell lines. Equal
amounts of cell lysate were processed by Western blotting.
As anticipated, IQGAP levels varied among the cell lines.
Those cells with higher levels of IQGAP1 have lower levels
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lower levels of IQGAP1 (Figure 1). In particular, Sk-Hep-
1, SNU475 and SNU387 cells had high IQGAP1 and low
IQGAP2 expression (Figure 1).
IQGAP1 Protein is Upregulated and IQGAP2 Protein is
Downregulated in Human HCC
The immunohistochemistry (IHC) data are summarized
in Table 2. By IHC, IQGAP1 was detected in the hepa-
tocytes of 5/28 (17.9%) normal livers, 0/4 (0.0%) hepatic
adenomas and 0/23 (0.0%) cirrhosis cases (Figure 2 and
Table 2). In contrast, the expression of IQGAP1 was dif-
fusely positive (>10% of tumor cells) in 69/82 (84.1%)
HCC specimens (Figure 2 and Table 2) (30/30 samples
from Brigham and Women’s Hospital and 39/52 sam-
ples from the TMA). The expression of IQGAP2 was
diffusely positive in the hepatocytes of 22/28 (78.6%)
normal livers, 4/4 (100.0%) hepatic adenomas and 23/23
(100.0%) cirrhosis cases (Figure 2 and Table 2). How-
ever, only 18/82 (22.0%) HCC specimens were positive
f o rI Q G A P 2( F i g u r e2a n dT a b l e2 )( 2 / 3 0s a m p l e sf r o m
Brigham and Women’s Hospital and 16/52 samples
from the TMA). Of note, only 3 of 11 (27.3%) HCC spe-
cimens retrieved from and stained at the tissue archives
of the Department of Pathology, Stony Brook University,
were positive for IQGAP1 and negative for IQGAP2
(data not shown). To maintain consistency in IHC stain-
ing and interpretation, these samples have been
excluded from our analysis. Although unlikely (as our
results are consistent between the HCC specimens from
Brigham and Women’s Hospital and those from the
TMA), we cannot rule out the possibility of differences
in tissue preparation processes at different institutions
accounting for these discrepant data. In all cases, the
sinusoidal lining cells also showed strong IQGAP1 and
IQGAP2 immunoreactivity.
IQGAP2 mRNA is Downregulated in Human HCC
mRNA expression analyses did not detect a significant
alteration of IQGAP1 expression in HCC at any stage,
n o rw a st h e r ead i f f e r e n c eb e t w e e nI Q G A P 1m R N A
levels in cancer and normal tissue (Figure 3). In con-
trast, expression of the IQGAP2 transcript in HCC spe-
cimens was significantly decreased (p < 0.05) compared
to normal livers (Figure 3), and the magnitude of this
decrease was progressive between normal tissue and
stage II HCC. No further statistically significant reduc-
tion was evident at stages III and IV. Interestingly, we
found that normal livers have significantly (~1000-fold)
more IQGAP2 mRNA than that of IQGAP1 (Figure 3).
The Iqgap2 Promoter is not Hypermethylated in HCC
To determine if IQGAP2 downregulation in HCC was due
to hypermethylation of the Iqgap2 gene promoter, we per-
formed pyrosequencing of bisulfite-treated genomic DNA
from patient tissues. Efficient genomic DNA extraction
requires a sufficient amount of FFPE tissue. Therefore,
only the surgically resected HCC specimens, and not the
biopsy or TMA specimens, were analyzed. 17 HCC speci-
mens, 3 hepatic adenomas, 8 cirrhosis cases and 6 normal
livers were used for methylation analysis. The overall
methylation level of the Iqgap2 promoter was 3.1% in
HCC specimens and 3.3% in normal livers (Figure 4 and
Additional File 3). The hepatic adenomas and cirrhosis
cases had Iqgap2 methylation levels comparable to that of
normal livers (2.3% and 3.3%, respectively). To exclude the
possibility that low methylation levels detected in FFPE
samples may be due to damage of the genomic DNA by
formalin, 2 snap-frozen HCC specimens and 3 normal
livers from the National Disease Research Interchange
(Philadelphia, PA) were also analyzed. In all cases, the
results obtained were similar to those from FFPE tissue
(Additional File 3).
Discussion
We recently showed that IQGAP1 and IQGAP2 have
opposing roles in a murine model of hepatic carcinogen-
esis [6]. In that study, Iqgap2
-/- mice developed age-
dependent HCC, whereas mice deficient in both Iqgap1
and Iqgap2 displayed relative protection against HCC
and showed significantly improved long-term survival.
These data suggest that, in HCC, IQGAP2 may repre-
sent a tumor suppressor and IQGAP1 an oncogene. In
the current study, we evaluated the expression of
IQGAP1 and IQGAP2 in human HCC. We showed that
a reciprocal relationship existed between IQGAP1 and
IQGAP2 expression in human liver cancer cell lines.
Furthermore, IQGAP2 was downregulated in 78.0% of
HCC specimens, and IQGAP1 protein was overex-
pressed in 84.1% of tumors. Finally, we demonstrated
that IQGAP2 mRNA is decreased in HCC compared to
normal livers (although we did not detect any significant
change in the IQGAP1 transcript), and showed that the
Iqgap2 promoter is not hypermethylated in HCC.
Viewed collectively, these da t as t r o n g l ys u g g e s tt h a t
IQGAP1 and IQGAP2 contribute to the pathogenesis of
HCC, and that these proteins are highly sensitive and
specific biomarkers of this type of tumor.
Our data indicate that Sk-Hep-1, SNU475 and
SNU387 cells have high levels of IQGAP1 and low levels
Table 2 Immunohistochemistry results
Diagnosis IQGAP1 (% Positive) IQGAP2 (% Positive)
Normal 5/28 (17.9) 22/28 (78.6)
Adenoma 0/4 (0.0) 4/4 (100.0)
Cirrhosis 0/23 (0.0) 23/23 (100.0)
Carcinoma 69/82 (84.1) 18/82 (22.0)
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and lack E-cadherin, while the other cell lines we stu-
died have E-cadherin and are epithelial [29]. Loss of E-
cadherin results in metastasis and a poor prognosis in
many tumors [30]. Congruent with this, microarray ana-
lysis revealed that genes involved in invasion and metas-
tasis are overexpressed in Sk-Hep-1, SNU475 and
SNU387 cells, but not in HepG2, Hep3B or Huh7 cells
[31] (which have low IQGAP1 and high IQGAP2
expression). Viewed collectively, these data suggest that
increased IQGAP1 and/or decreased IQGAP2 expres-
s i o nm a yb eac h a r a c t e r i s t i co fam o r ei n v a s i v ea n d
metastatic HCC phenotype. Nevertheless, as we did not
o b s e r v ead i f f e r e n c ei nI Q G A P 1p o s i t i v i t yo rI Q G A P 2
negativity between different HCC grades, it is also possi-
ble that these observations are a consequence of cell
line immortalization. Future studies are necessary to
reconcile these discrepant data.
Differentiation of HCC from benign hepatocellular
tumors, such as hepatic adenomas, macroregenerative
nodules, and high grade dysplastic nodules, can be diffi-
cult morphologically [32,33]. Several immunohistochem-
ical markers, such as CD10, polyclonal CEA, and Hep
Par1 may be used to help determine a hepatocellular
origin of a particular lesion, but are not helpful in differ-
entiating benign from malignant tumors [34,35]. More-
over, Glypican-3, a heparin-sulfate proteoglycan recently
reported to show a high degree of specificity for HCC
versus benign hepatocellular proliferations, is limited by
its relatively low sensitivity [33,36]. In the current study,
we demonstrated a high degree of sensitivity and specifi-
city for IQGAP1 positivity, and IQGAP2 negativity, in
HCC. Indeed, 84.1% of HCCs were positive for
IQGAP1, whereas all hepatic adenomas, cirrhosis cases,
and most (82.1%) normal livers were IQGAP1 negative.
Similarly, IQGAP2 was negative in 78.0% of HCCs, but
Figure 2 IQGAP1 and IQGAP2 protein expression is altered in hepatocellular carcinoma. Representative immunohistochemistry images
showing IQGAP1 and IQGAP2 protein expression in normal (b-c), adenoma (e-f), cirrhosis (h-i) and carcinoma (k-l). Hematoxylin and eosin (H&E)
stained images corresponding to each case are also shown (a, d, g, j). Scale bar represents 10 μm, and the final magnification is 400×.
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mas, cirrhosis cases and normal livers, respectively.
Based on these data, we propose that IQGAP1 and
IQGAP2, either alone or in combination, are highly sen-
sitive and specific biomarkers of HCC. As a result, their
use may be valuable in routine diagnostic pathology.
As mentioned above, our qRT-PCR results showed that
IQGAP2 transcript expression in human HCC was signif-
icantly lower than normal tissue. To our knowledge, we
are the first group to report this finding in human HCC.
The only other report of reduced IQGAP2 mRNA in
HCC comes from our previous study in mice [6]. Consis-
tent with our current findings, IHC revealed that
IQGAP2 protein, which was abundant in normal livers,
was undetectable in most (78.0%) HCC specimens stu-
died. Our qRT-PCR results also indicated that IQGAP1
mRNA expression did not differ significantly between
normal livers and HCC. These findings are different from
both our current IHC data, and mRNA data observed by
other investigators [37]. Several factors may account for
these differences, including the source of the original
samples. For instance, our qRT-PCR experiments were
performed on a commercial cDNA array for which no
information regarding the etiology of HCC was available.
Furthermore, it has been demonstrated that the expres-
sion of certain genes in HCC may differ depending on a
patient’s HBV and HCV status [38,39]. Moreover,
although we could not detect IQGAP1 protein in normal
hepatocytes, it was expressed in Kupffer cells. Thus, if the
cDNA in the array specimens was crudely extracted from
homogenized liver, rather than from hepatocytes exclu-
sively, possible changes in IQGAP1 mRNA expression
may have been masked by mRNA from other cell types.
Recent examination of microarray datasets of human
HCC revealed that the Iqgap1 gene is significantly upre-
gulated in human HCC specimens compared to normal
livers [37]. Conversely, in agreement with our results,
Liao and colleagues reported no significant difference in
Iqgap1 expression between normal livers and HCC [40].
A more quantitative assessment of Iqgap1 gene expres-
sion in a larger cohort of HCC specimens is necessary to
reconcile these discrepancies.
Silencing of tumor suppressor genes by promoter
hypermethylation is the most extensively studied epige-
netic mechanism in tumorigenesis [41-43]. In our cur-
rent study, we hypothesized that downregulation of
IQGAP2 expression in HCC specimens may be due to
aberrant methylation of the Iqgap2 promoter. To test
this theory, we utilized pyrosequencing of bisulfite-
treated DNA, and evaluated the Iqgap2 promoter
methylation profile of our HCC specimens. Pyrose-
quencing is a quantitative technique which allows for
precise determination of methylation of individual
CpG sites within a specific CpG island. Additionally, it
has been shown to be effective for methylation analysis
of FFPE tissues [44]. Other commonly used methyla-
tion analysis methods, such as methylation specific
PCR, do not allow resolution of single-CpG sites
(which is especially important for the analysis of genes
with heterogeneous methylation patterns). A methyla-
tion level of ≤ 5% is considered background noise, and
thus has questionable significance [45]. The overall
Iqgap2 methylation levels detected in our current
study were less than 5% in both FFPE HCC specimens
and in normal livers. In contrast, Iqgap2 hypermethyla-
tion was detected in Kato III cells, suggesting that our
pyrosequencing assay was technically sound. We con-
firmed the results of our FFPE HCC specimens and
normal livers using an independent set of snap-frozen
patient tissue. Viewed collectively, these data strongly
suggest that methylation of the Iqgap2 promoter is not
the principle mechanism by which IQGAP2 is downre-
gulated in HCC. It has been reported that ectopic
expression of specific miRNAs in HCC cells results in
silencing of Iqgap1 and a concomitant decrease in cell
proliferation [46]. Thus, it is possible that IQGAP2
expression in HCC may also be regulated by miRNAs,
instead of by promoter methylation.
Figure 3 IQGAP2 RNA transcript expression is altered in
hepatocellular carcinoma. IQGAP1 (top panel) and IQGAP2
(bottom panel) mRNA expression in cDNAs from patients with HCC
and normal livers was evaluated by qRT-PCR. The boxed area
represents 50% of samples (from the 25
th to the 75
th percentile)
and the band inside the box represents the median. *, p < 0.05
versus normal livers.
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IQGAP2 expression in human HCC. Based on the data
presented here, the stochiometry between IQGAP1 and
IQGAP2 is central to hepatocellular carcinogenesis. The
precise mechanism by which IQGAPs contribute to neo-
plastic transformation and tumor progression is still
poorly understood. Numerous IQGAP1 binding partners
are known to be involved in tumorigenesis [22]. In con-
trast, little is known about the proteins with which
IQGAP2 interacts. Future studies will provide insight
into the role of IQGAPs in liver cancer.
Conclusions
We have shown that IQGAP2 expression is downregu-
lated in more invasive and metastatic liver cancer cell
lines and most human HCC tissue. Furthermore, our
data indicate that this downregulation is not a result of
hypermethylation of the Iqgap2 promoter. In contrast,
IQGAP1 is overexpressed in more aggressive liver can-
cer cell lines and the majority of HCC specimens. While
future studies will address the mechanism underlying
this reciprocal change, these findings validate the rele-
vance of the Iqgap2
-/- mouse model to human disease.
Immunostaining of IQGAP1 and IQGAP2 may aid in
the diagnosis of HCC, and their pharmacologic modula-
tion may represent a novel therapeutic strategy for the
treatment of liver cancer.
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